Renal transplantation: A quarter century of achievement

Seminars in Nephrology

Volumn 17, Issue 3, 1997, Pages 188-195

  Morris, Peter J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHRONIC KIDNEY FAILURE; DONOR; GRAFT REJECTION; GRAFT SURVIVAL; HISTORY; HUMAN; KIDNEY TRANSPLANTATION;

GRAFT REJECTION; GRAFT SURVIVAL; HISTORY, 20TH CENTURY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; TISSUE DONORS;

EID: 0031136491     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Hamilton D: Kidney transplantation: A history, in Morris PJ (ed): Kidney Transplantation: Principles and Practice, 4th ed. Philadelphia, PA, Saunders, 1994, pp 1-7
2. Hume DM, Merrill JP, Miller BF, Thorn GW: Experiences with renal homotransplantation in the human: Report of nine cases. J Clin Invest 34:327-382, 1955
3. Murray JE, Merrill JP, Harrison JH: Kidney transplantation between seven pairs of identical twins. Ann Surg 148:343-359, 1958
4. Schwartz R, Dameshek W: Drug-induced immunological tolerance. Nature 183:1682-1683, 1959
5. Calne RY: The rejection of renal homografts: Inhibition in dogs by 6-mercapto-purine. Lancet 1:417-418, 1960
6. Zukoski CF, Lee HM, Hume DM.-The effect of 6-mercaptopurine on renal homograft survival in the dog. Surg Forum 11:47, 1960
7. Murray JW, Merrill JP, Harrison JH, et al: Prolonged survival of human kidney homografts by immunosuppressive drug therapy. N Engl J Med 268:1315-1323, 1963
8. Goodwin WE, Mims MM, Kaufman JJ: Human renal transplant III. Technical problems encountered in six cases of kidney homotransplantation. Trans Am Assoc Genitourin Surg 54:116, 1962
9. Starzl TE, Marchioro TL, Waddell WR: The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 117:385-395, 1963
10. Morris PJ, Chan L, French ME, et al: Low-dose oral prednisolone in renal transplantation Lancet 1:525-527, 1982
11. Powelson JA, Cosimi AB: Antilymphocyte globulin and monclonal antibodies, in Morris PJ (ed): Kidney Transplantation: Principles and Practice, 4th ed. Philadelphia, PA, Saunders, 1994, pp 215-232
12. Opelz G, Sengar DPS, Mickey MR, et al: Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 5:253-259, 1973
13. Borel JF, Feurer C, Magnee C, et al: Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32:1017-1025, 1977
14. Calne RY, RoIIes K, White DJG, et al: Cyclosporin A initially as the only immunosuppressant in 36 recipients of cadaveric organs: 32 kidney, 2 pancreas and 2 livers. Lancet 2:1033-1036, 1979
15. Powles RL, Barrett Ai, Clink H, et al: Cyclosporin A for the treatment of graft versus host disease in man. Lancet 2:327-329, 1980
16. European Multicentre Trial: Cyclosporin A as sole immunosuppressive agent in recipients of kidney allograft from cadaver donors. Lancet 2:57-60, 1982
17. Morris PJ: Cyclosporine, in Morris PJ (ed): Kidney Transplantation: Principles and Practice, 4th ed. Philadelphia, PA, Saunders, 1994, pp 179-201
18. Barone G, Chang CT, Choc-MG Jr, et al: The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation 61:875-880, 1996
19. Schreiber SL, Crabtree GR: The mechanism of action of cyclosporinA and FK506. Immunol Today 13:136-142, 1992
20. Starzl TE, Todo S, Fung J, et al: FK506 for liver, kidney, and pancreas transplantation. Lancet 2:1000-1004, 1989
21. Japanese FK506 Study Group: Japanese study of FK506 on kidney transplantation: Results of late phase II study. Transplant Proc 25:649-654, 1993b
22. The US Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 331:1110-1115, 1994
23. European FK506 Multicentre Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 2:423-428, 1994
24. Shapiro R, Jordan ML, Scantlebury VP, et al: A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation 59:485-490, 1995
25. Eberhard OK, Kliem V, Oldhafer K, et al: How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. Transplantation 61:1345-1349, 1996
26. Morris RE: Rapamycin:antifungal, antitumor, antiproliferative and immunosuppressive macrolides. Transplant Rev 6:39-87, 1992
27. Brattstrom C, Tyden G, Sawe J, et al: A randomized double-blind, placebo-controlled study to determine safety, tolerance and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc 28:985-986, 1996
28. Sigal NH, Dumont FJ: Cyclosporin A, FK506, and rapamycin: pharmacologie probes of lymphocyte signal transduction. Ann Rev Immunol 10:519-560, 1992
29. Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287, 1991
30. Knight R, Ferraresso M, Serino F, et al: Low dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. Transplantation 55:947-949, 1993
31. Eugui EM, Almquist S, Muller CD, et al: Lymphocyteselective cytostatic and immunosuppressive effects of mycophenolic acid invitro: role of deoxyguanosinenucleotide depletion. Scand J Immunol 33:161-173, 1991a
32. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients (US Renal Transplant Mycophenolate Mofetil Study Group). Transplantation 60:225-232, 1995
33. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
34. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029-1037. 1996
35. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 61:722-729, 1996
36. Steinmuller DR, Hayes JM, Novick AC, et al: Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 52:67-71, 1991
37. Lazarovitz Al, Rochon J, Banks L, et al: Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J Immunol 150:5163-5174, 1993
38. Haug CE, Colvin RB, Delmonico FL, et al: A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation 55:766-772, 1993
39. Knight RJ, Kurrle R, McClain J, et al: Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA031) directed toward the human alpha/beta-T cell receptor. Transplantation 57:1581-1588, 1994
40. Kirkman RL, Shapiro ME, Carpenter CB, et al: A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 51:107-113, 1991
41. Hourmant M, Le-Mauff B, Le-Meur Y, et al: Administration of an anti-CDU a monoclonal antibody in recipients of kidney transplantation. A pilot study. Transplantation 58:377-380, 1994
42. Goldberg LC, Bradley JA, Connolly J, et al: AntiCD45 monoclonal antibody perfusion of human renal allografts prior to transplantation. A safety and immunohistological study. CD45 Study Group. Transplantation 59:1285-1293, 1995
43. van Velder T, Zietse R, Mulder AH, et al: A doubleblind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation. Transplantation 60:248-252, 1995
44. Morris PJ: Results of renal transplantation, in Morris PJ (ed): Kidney Transplantation: Principles and Practice 4th ed. Philadelphia, PA, Saunders, 1994, pp 504-523
45. Terasaki PI, Cecka JM, Gjertson DW, et al: High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 333:333-336, 1995
46. Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 172:603, 1953
47. Pearson TC, Madsen JC, Larsen C, et al: Induction of transplantation tolerance in the adult using donor antigen and anti-CD4 monoclonal antibody. Transplantation 54:475-483, 1992
48. Sykes M, Sachs DH: Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 9:23-27, 1988
49. Madsen JC, Superina RA, Wood KJ, et al: Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes. Nature 332:161-164, 1988
50. Anderson CB, Brennan D, Keller C, et al: Beneficial effects of donor specific transfusions on long-term renal allograft function. Transplant Proc 27:991-994, 1995
51. Barber WH, Mankin JA, Laskow DA, et al: Longterm results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51:70-75, 1991
52. Starzl TE, Demetris AJ, Murase N, et al: Cell migration, chimerism and graft acceptance. Lancet 339:1579-1582, 1992
53. Bach FH, Robson SC, Winkler H, et al: Barriers to xenotransplantation. Nat Med 1:869-873, 1995
54. Diamond LE, McCurry KR, Martin MJ, et al: Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 61:1241-1249, 1996
55. Tearle RG, Tange MJ, Zannettino ZL, et al: The alpha1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation 61:13-19, 1996
56. Cairns T, Lee J, Goldberg L, et al: Inhibition of the pig to human xenograft reaction, using soluble Gal alpha 13Gal and Gal alpha l-3Gal beta MGlcNac. Transplantation 60:1202-1207, 1995
57. Kroshus TJ, Rollins SA, Dalmasso AP, et al: Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60:11941202, 1995
58. Sandrin MS, Fodor WL, Mouhtouris E, et al: Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nat Med 1:1261-1267, 1995
59. Magee JC, Collins BH, Harland RC, et al: Immunoglobulin prevents complement-mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 96:2404-2412, 1995